January 21, 2008 - Daiichi Sankyo, Inc. announced that the United States Food and Drug Administration (FDA) has approved Welchol (colesevelam HCl) to improve glycemic control (measured as hemoglobin A1C) in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas, or insulin, either alone or in combination with other anti-diabetic agents. Welchol is now the first and only medication approved to reduce both glucose levels and low density lipoprotein cholesterol levels (LDL-C)... [PDF] Daiichi Sankyo's Press Release-
Friday, January 25, 2008
Daiichi Sankyo's Welchol, FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
January 21, 2008 - Daiichi Sankyo, Inc. announced that the United States Food and Drug Administration (FDA) has approved Welchol (colesevelam HCl) to improve glycemic control (measured as hemoglobin A1C) in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas, or insulin, either alone or in combination with other anti-diabetic agents. Welchol is now the first and only medication approved to reduce both glucose levels and low density lipoprotein cholesterol levels (LDL-C)... [PDF] Daiichi Sankyo's Press Release-
